2,885 Shares in Jazz Pharmaceuticals PLC (JAZZ) Acquired by California State Teachers Retirement System

California State Teachers Retirement System bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,885 shares of the specialty pharmaceutical company’s stock, valued at approximately $449,000.

A number of other institutional investors and hedge funds have also modified their holdings of JAZZ. World Asset Management Inc raised its holdings in Jazz Pharmaceuticals by 1.9% in the 2nd quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock worth $224,000 after purchasing an additional 27 shares during the period. Profund Advisors LLC grew its position in Jazz Pharmaceuticals by 1.3% in the second quarter. Profund Advisors LLC now owns 2,915 shares of the specialty pharmaceutical company’s stock worth $453,000 after acquiring an additional 38 shares in the last quarter. Advisors Asset Management Inc. boosted its position in shares of Jazz Pharmaceuticals by 0.5% during the second quarter. Advisors Asset Management Inc. now owns 17,882 shares of the specialty pharmaceutical company’s stock valued at $2,781,000 after buying an additional 86 shares during the period. Victory Capital Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 4.0% during the second quarter. Victory Capital Management Inc. now owns 3,410 shares of the specialty pharmaceutical company’s stock valued at $530,000 after acquiring an additional 132 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Jazz Pharmaceuticals by 3.3% during the second quarter. Alliancebernstein L.P. now owns 4,352 shares of the specialty pharmaceutical company’s stock valued at $677,000 after acquiring an additional 141 shares in the last quarter. Institutional investors and hedge funds own 91.30% of the company’s stock.

In other Jazz Pharmaceuticals news, Director Patrick G. Enright sold 352 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.19, for a total value of $46,882.88. Following the sale, the director now directly owns 1,365 shares of the company’s stock, valued at $181,804.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction on Friday, November 17th. The shares were sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the completion of the sale, the senior vice president now directly owns 28,383 shares in the company, valued at $3,786,859.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,352 shares of company stock worth $1,417,763. 4.30% of the stock is owned by corporate insiders.

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at $138.97 on Friday. Jazz Pharmaceuticals PLC has a 1-year low of $101.37 and a 1-year high of $163.75. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. The company has a market cap of $8,083.13, a price-to-earnings ratio of 16.92, a price-to-earnings-growth ratio of 0.87 and a beta of 0.98.

JAZZ has been the subject of a number of recent research reports. Cowen set a $190.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, August 21st. HC Wainwright started coverage on Jazz Pharmaceuticals in a research report on Friday, August 25th. They set a “neutral” rating and a $144.00 price target on the stock. Wells Fargo & Company reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 29th. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, August 30th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 29th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $181.28.

COPYRIGHT VIOLATION WARNING: “2,885 Shares in Jazz Pharmaceuticals PLC (JAZZ) Acquired by California State Teachers Retirement System” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://www.dispatchtribunal.com/2017/12/09/2885-shares-in-jazz-pharmaceuticals-plc-jazz-acquired-by-california-state-teachers-retirement-system.html.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply